Jim Kastenmayer
Conseiller Juridique Général chez ARRIVENT BIOPHARMA, INC.
Fortune : 137 010 $ au 30/06/2024
Profil
Jim Kastenmayer is currently the Secretary & General Counsel at Arrivent BioPharma, Inc. He previously worked as the Legal Director & Senior Patent Director at AstraZeneca PLC from 2012 to 2019.
He also worked as the Secretary & General Counsel at Spyre Therapeutics, Inc. from 2021 to 2023 and at Viela Bio, Inc. from 2020 to 2021.
Additionally, he worked as an IP Counsel at Medimmune, Inc. Dr. Kastenmayer holds a doctorate degree from Michigan State University, an undergraduate degree from the University of Virginia, and a graduate degree from Georgetown University Law Center.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
0,02% | 25/01/2024 | 7 386 ( 0,02% ) | 137 010 $ | 30/06/2024 |
Postes actifs de Jim Kastenmayer
| Sociétés | Poste | Début |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | Conseiller Juridique Général | 01/09/2023 |
Anciens postes connus de Jim Kastenmayer
| Sociétés | Poste | Fin |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Directeur Général | 29/11/2022 |
| VIELA BIO, INC. | Conseiller Juridique Général | 01/03/2021 |
| ASTRAZENECA PLC | Conseiller Juridique Général | 01/12/2019 |
| Medimmune, Inc. | Corporate Officer/Principal | - |
Formation de Jim Kastenmayer
| Georgetown University Law Center | Graduate Degree |
| Michigan State University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
